Market closed

BridgeBio Pharma/$BBIO

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About BridgeBio Pharma

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Ticker

$BBIO

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Palo Alto, United States

Employees

553

Website

bridgebio.com

BridgeBio Pharma Metrics

BasicAdvanced

$6.4B

-

-$2.41

1.09 -

Price and volume

Market cap

$6.4B

Beta

1.09

52-week high

$41.04

52-week low

$21.62

Average daily volume

Financial strength

Current ratio

3.619

Quick ratio

2.172

Long term debt to equity

-141.592

Total debt to equity

-141.97

Interest coverage (TTM)

-5.75%

Management effectiveness

Return on assets (TTM)

-48.88%

Return on equity (TTM)

37.00%

Valuation

Price to revenue (TTM)

28.242

Price to book

-5.18

Price to tangible book (TTM)

-5.08

Price to free cash flow (TTM)

-13.477

Growth

Revenue change (TTM)

2,209.77%

Earnings per share change (TTM)

-38.51%

3-year revenue growth (CAGR)

56.37%

3-year earnings per share growth (CAGR)

-14.75%

What the Analysts think about BridgeBio Pharma

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for BridgeBio Pharma stock.

BridgeBio Pharma Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

BridgeBio Pharma Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

BridgeBio Pharma News

AllArticlesVideos

BridgeBio CEO Neil Kumar: Our heart disease drug staves off death and hospitalization

CNBC Television·14 hours ago

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Investors Business Daily·2 days ago

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

GlobeNewsWire·2 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BBIO

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BridgeBio Pharma stock?

BridgeBio Pharma (BBIO) has a market cap of $6.4B as of January 15, 2025.

What is the P/E ratio for BridgeBio Pharma stock?

The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of January 15, 2025.

Does BridgeBio Pharma stock pay dividends?

No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next BridgeBio Pharma dividend payment date?

BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.

What is the beta indicator for BridgeBio Pharma?

BridgeBio Pharma (BBIO) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.